Hepatitis C virus-induced upregulation of microRNA miR-146a-5p in hepatocytes promotes viral infection and deregulates metabolic pathways associated with liver disease pathogenesis

Journal of Virology

Volumn 90, Issue 14, 2016, Pages 6387-6400

  Bandiera, Simonetta ^a,b   Pernot, Sophie ^a,b   El Saghire, Hussein ^a,b   Durand, Sarah C ^a,b   Thumann, Christine ^a,b   Crouchet, Emilie ^a,b   Ye, Tao ^b,c   Fofana, Isabel ^d   Oudot, Marine A ^a,b   Barths, Jochen ^a,b   Schuster, Catherine ^a,b   Pessaux, Patrick ^a,b,e   Heim, Markus H ^d   Baumert, Thomas F ^a,b,e   Zeisel, Mirjam B ^a,b  

^a Hopitaux Universitaires de Strasbourg   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c CNRS   (France)

^d UNIVERSITY OF BASEL   (Switzerland)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 146A 5P; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MIRN146 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE TARGETING; GENETIC ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER DISEASE; MALE; NONHUMAN; PRIORITY JOURNAL; RNA SEQUENCE; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS LOAD; VIRUS REPLICATION; CYTOLOGY; GENE EXPRESSION PROFILING; GENETICS; HEPACIVIRUS; HOST PATHOGEN INTERACTION; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; TRANSCRIPTION INITIATION; VIROLOGY;

ADULT; AGED; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION PROFILING; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HOST-PATHOGEN INTERACTIONS; HUMANS; LIVER NEOPLASMS; MALE; METABOLIC NETWORKS AND PATHWAYS; MICRORNAS; MIDDLE AGED; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84977598620     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00619-16     Document Type: Article

References (74)

1. Chung RT, Baumert TF. 2014. Curing chronic hepatitis C-the arc of a medical triumph. N Engl J Med 370:1576-1578. http://dx.doi.org/10.1056/NEJMp1400986.
2. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. 2012. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308: 2584-2593. http://dx.doi.org/10.1001/jama.2012.144878.
3. Szabo G, Bala S. 2013. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 10:542-552. http://dx.doi.org/10.1038/nrgastro.2013.87.
4. Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. 2015. miR-122-a key factor and therapeutic target in liver disease. J Hepatol 62:448-457. http://dx.doi.org/10.1016/j.jhep.2014.10.004.
5. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. 2005. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309:1577-1581. http://dx.doi.org/10.1126/science.1113329.
6. Henke JI, Goergen D, Zheng J, Song Y, Schuttler CG, Fehr C, Junemann C, Niepmann M. 2008. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J 27:3300-3310. http://dx.doi.org/10.1038/emboj.2008.244.
7. Li Y, Masaki T, Yamane D, McGivern DR, Lemon SM. 2013. Competing and noncompeting activities of miR-122 and the 5= exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc Natl Acad Sci U S A 110: 1881-1886. http://dx.doi.org/10.1073/pnas.1213515110.
8. Shrivastava S, Mukherjee A, Ray RB. 2013. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol 5:479-486. http://dx.doi.org/10.4254/wjh.v5.i9.479.
9. Gragnani L, Piluso A, Fognani E, Zignego AL. 2015. MicroRNA expression in hepatitis C virus-related malignancies: a brief review. World J Gastroenterol 21:8562-8568. http://dx.doi.org/10.3748/wjg.v21.i28.8562.
10. Fan HX, Tang H. 2014. Complex interactions between microRNAs and hepatitis B/C viruses. World J Gastroenterol 20:13477-13492. http://dx.doi.org/10.3748/wjg.v20.i37.13477.
11. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M. 2008. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 47: 1223-1232. http://dx.doi.org/10.1002/hep.22158.
12. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S. 2009. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49:1098-1112. http://dx.doi.org/10.1002/hep.22749.
13. Steinmann E, Pietschmann T. 2013. Cell culture systems for hepatitis C virus. Curr Top Microbiol Immunol 369:17-48. http://dx.doi.org/10.1007/978-3-642-27340-7_2.
14. Sainz B, Jr, Chisari FV. 2006. Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. J Virol 80:10253-10257. http://dx.doi.org/10.1128/JVI.01059-06.
15. Bauhofer O, Ruggieri A, Schmid B, Schirmacher P, Bartenschlager R. 2012. Persistence ofHCVin quiescent hepatic cells under conditions of an interferon-induced antiviral response. Gastroenterology 143:429.e8-438.e8. http://dx.doi.org/10.1053/j.gastro.2012.04.018.
16. Xiao F, Fofana I, Thumann C, Mailly L, Alles R, Robinet E, Meyer N, Schaeffer M, Habersetzer F, Doffoel M, Leyssen P, Neyts J, Zeisel MB, Baumert TF. 2015. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut 64:483-494. http://dx.doi.org/10.1136/gutjnl-2013-306155.
17. Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset FL, Ball JK, Patel AH. 2005. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 79:11095-11104. http://dx.doi.org/10.1128/JVI.79.17.11095-11104.2005.
18. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102:9294-9299. http://dx.doi.org/10.1073/pnas.0503596102.
19. Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, Mee C, Soulier E, Royer C, Lambotin M, Grunert F, Dao Thi VL, Dreux M, Cosset FL, McKeating JA, Schuster C, Baumert TF. 2010. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 51:1144-1157. http://dx.doi.org/10.1002/hep.23445.
20. Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FH, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, Lutgehetmann M, Volz T, Davis C, Harris HJ, Mee CJ, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim MH, Neunlist M, Zeisel MB, Dandri M, McKeating JA, Robinet E, Baumert TF. 2015. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol 33:549-554. http://dx.doi.org/10.1038/nbt.3179.
21. Bartosch B, Dubuisson J, Cosset FL. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197:633-642. http://dx.doi.org/10.1084/jem.20021756.
22. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoel M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF. 2011. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17:589-595. http://dx.doi.org/10.1038/nm.2341.
23. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791-796. http://dx.doi.org/10.1038/nm1268.
24. Merz A, Long G, Hiet MS, Brugger B, Chlanda P, Andre P, Wieland F, Krijnse-Locker J, Bartenschlager R. 2011. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem 286:3018-3032. http://dx.doi.org/10.1074/jbc.M110.175018.
25. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, Buhler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R. 2011. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 9:32-45. http://dx.doi.org/10.1016/j.chom.2010.12.002.
26. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. http://dx.doi.org/10.1126/science.1114016.
27. Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, Fafi-Kremer S, Soulier E, Royer C, Thumann C, Mee CJ, McKeating JA, Dragic T, Pessaux P, Stoll-Keller F, Schuster C, Thompson J, Baumert TF. 2010. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 139:953-964, 964.e1-964.e4. http://dx.doi.org/10.1053/j.gastro.2010.05.073.
28. Da Costa D, Turek M, Felmlee DJ, Girardi E, Pfeffer S, Long G, Bartenschlager R, Zeisel MB, Baumert TF. 2012. Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. J Virol 86:11919-11925. http://dx.doi.org/10.1128/JVI.01066-12.
29. Mobuchon L, Marthey S, Le Guillou S, Laloe D, Le Provost F, Leroux C. 2015. Food deprivation affects the miRNome in the lactating goat mammary gland. PLoS One 10:e0140111. http://dx.doi.org/10.1371/journal.pone.0140111.
30. Buck AH, Perot J, Chisholm MA, Kumar DS, Tuddenham L, Cognat V, Marcinowski L, Dolken L, Pfeffer S. 2010. Post-transcriptional regulation of miR-27 in murine cytomegalovirus infection. RNA 16:307-315. http://dx.doi.org/10.1261/rna.1819210.
31. Griffiths-Jones S. 2004. The microRNA Registry. Nucleic Acids Res 32: D109-D111. http://dx.doi.org/10.1093/nar/gkh023.
32. Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101-1108. http://dx.doi.org/10.1038/nprot.2008.73.
33. Adamo A, Atashpaz S, Germain PL, Zanella M, D'Agostino G, Albertin V, Chenoweth J, Micale L, Fusco C, Unger C, Augello B, Palumbo O, Hamilton B, Carella M, Donti E, Pruneri G, Selicorni A, Biamino E, Prontera P, McKay R, Merla G, Testa G. 2015. 7q11.23 dosagedependent dysregulation in human pluripotent stem cells affects transcriptional programs in disease-relevant lineages. Nat Genet 47:132-141. http://dx.doi.org/10.1038/ng.3169.
34. Li Q, Brass AL, Ng A, Hu Z, Xavier RJ, Liang TJ, Elledge SJ. 2009. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A 106:16410-16415. http://dx.doi.org/10.1073/pnas.0907439106.
35. Benga WJ, Krieger SE, Dimitrova M, Zeisel MB, Parnot M, Lupberger J, Hildt E, Luo G, McLauchlan J, Baumert TF, Schuster C. 2010. Apolipoprotein E interacts with hepatitisCvirus nonstructural protein 5A and determines assembly of infectious particles. Hepatology 51:43-53. http://dx.doi.org/10.1002/hep.23278.
36. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 103: 7408-7413. http://dx.doi.org/10.1073/pnas.0504877103.
37. Gastaminza P, Kapadia SB, Chisari FV. 2006. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol 80:11074-11081. http://dx.doi.org/10.1128/JVI.01150-06.
38. Langmead B, Trapnell C, Pop M, Salzberg SL. 2009. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 10:R25. http://dx.doi.org/10.1186/gb-2009-10-3-r25.
39. Chen CJ, Servant N, Toedling J, Sarazin A, Marchais A, Duvernois-Berthet E, Cognat V, Colot V, Voinnet O, Heard E, Ciaudo C, Barillot E. 2012. ncPRO-seq: a tool for annotation and profiling of ncRNAs in sRNA-seq data. Bioinformatics 28:3147-3149. http://dx.doi.org/10.1093/bioinformatics/bts587.
40. Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. http://dx.doi.org/10.1186/s13059-014-0550-8.
41. Dembele D, Kastner P. 2014. Fold change rank ordering statistics: a new method for detecting differentially expressed genes. BMC Bioinformatics 15:14. http://dx.doi.org/10.1186/1471-2105-15-14.
42. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. 2011. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27:1739-1740. http://dx.doi.org/10.1093/bioinformatics/btr260.
43. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545-15550. http://dx.doi.org/10.1073/pnas.0506580102.
44. Lu TP, Lee CY, Tsai MH, Chiu YC, Hsiao CK, Lai LC, Chuang EY. 2012. miRSystem: an integrated system for characterizing enriched functions and pathways of microRNA targets. PLoS One 7:e42390. http://dx.doi.org/10.1371/journal.pone.0042390.
45. Tuddenham L, Jung JS, Chane-Woon-Ming B, Dolken L, Pfeffer S. 2012. Small RNA deep sequencing identifies microRNAs and other small noncoding RNAs from human herpesvirus 6B. J Virol 86:1638-1649. http://dx.doi.org/10.1128/JVI.05911-11.
46. Raychaudhuri S, Fontanes V, Barat B, Dasgupta A. 2009. Activation of ribosomalRNAtranscription by hepatitisCvirus involves upstream binding factor phosphorylation via induction of cyclin D1. Cancer Res 69: 2057-2064. http://dx.doi.org/10.1158/0008-5472.CAN-08-3468.
47. Chen Y, Chen J, Wang H, Shi J, Wu K, Liu S, Liu Y, Wu J. 2013. HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. PLoS Pathog 9:e1003248. http://dx.doi.org/10.1371/journal.ppat.1003248.
48. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD. 2008. Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 14:419-427. http://dx.doi.org/10.1158/1078-0432.CCR-07-0523.
49. Marquez RT, Bandyopadhyay S, Wendlandt EB, Keck K, Hoffer BA, Icardi MS, Christensen RN, Schmidt WN, McCaffrey AP. 2010. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 90: 1727-1736. http://dx.doi.org/10.1038/labinvest.2010.126.
50. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. 2007. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133:647-658. http://dx.doi.org/10.1053/j.gastro.2007.05.022.
51. Bao L, Yan Y, Xu C, Ji W, Shen S, Xu G, Zeng Y, Sun B, Qian H, Chen L, Wu M, Su C, Chen J. 2013. MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett 337:226-236. http://dx.doi.org/10.1016/j.canlet.2013.05.007.
52. Taganov KD, Boldin MP, Chang KJ, Baltimore D. 2006. NF-kappaBdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 103:12481-12486. http://dx.doi.org/10.1073/pnas.0605298103.
53. Bala S, Tilahun Y, Taha O, Alao H, Kodys K, Catalano D, Szabo G. 2012. Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J Transl Med 10:151. http://dx.doi.org/10.1186/1479-5876-10-151.
54. Zhang Z, Zhang Y, Sun XX, Ma X, Chen ZN. 2015. microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma. Mol Cancer 14:5. http://dx.doi.org/10.1186/1476-4598-14-5.
55. Qian H, Deng X, Huang ZW, Wei J, Ding CH, Feng RX, Zeng X, Chen YX, Ding J, Qiu L, Hu ZL, Zhang X, Wang HY, Zhang JP, Xie WF. 2015. An HNF1alpha-regulated feedback circuit modulates hepatic fibrogenesis via the crosstalk between hepatocytes and hepatic stellate cells. Cell Res 25:930-945. http://dx.doi.org/10.1038/cr.2015.84.
56. Cameron JE, Yin Q, Fewell C, Lacey M, McBride J, Wang X, Lin Z, Schaefer BC, Flemington EK. 2008. Epstein-Barr virus latent membrane protein 1 induces cellular microRNA miR-146a, a modulator of lymphocyte signaling pathways. J Virol 82:1946-1958. http://dx.doi.org/10.1128/JVI.02136-07.
57. Ma X, Becker Buscaglia LE, Barker JR, Li Y. 2011. MicroRNAs in NF-kappaB signaling. J Mol Cell Biol 3:159-166. http://dx.doi.org/10.1093/jmcb/mjr007.
58. Gong G, Waris G, Tanveer R, Siddiqui A. 2001. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 98:9599-9604. http://dx.doi.org/10.1073/pnas.171311298.
59. Sanda T, Iida S, Ogura H, Asamitsu K, Murata T, Bacon KB, Ueda R, Okamoto T. 2005. Growth inhibition of multiple myeloma cells by a novel IkappaB kinase inhibitor. Clin Cancer Res 11:1974-1982. http://dx.doi.org/10.1158/1078-0432.CCR-04-1936.
60. Zhang HX, Liu ZX, Sun YP, Zhu J, Lu SY, Liu XS, Huang QH, Xie YY, Zhu HB, Dang SY, Chen HF, Zheng GY, Li YX, Kuang Y, Fei J, Chen SJ, Chen Z, Wang ZG. 2013. Rig-I regulates NF-kappaB activity through binding to Nf-kappab1 3=-UTR mRNA. Proc Natl Acad Sci U S A 110: 6459-6464. http://dx.doi.org/10.1073/pnas.1304432110.
61. Li WC, Ye SL, Sun RX, Liu YK, Tang ZY, Kim Y, Karras JG, Zhang H. 2006. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res 12:7140-7148. http://dx.doi.org/10.1158/1078-0432.CCR-06-0484.
62. Cantor JR, Sabatini DM. 2012. Cancer cell metabolism: one hallmark, many faces. Cancer Discov 2:881-898. http://dx.doi.org/10.1158/2159-8290.CD-12-0345.
63. Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. 2014. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol 61:S79-S90. http://dx.doi.org/10.1016/j.jhep.2014.07.010.
64. Zhu K, Pan Q, Zhang X, Kong LQ, Fan J, Dai Z, Wang L, Yang XR, Hu J, Wan JL, Zhao YM, Tao ZH, Chai ZT, Zeng HY, Tang ZY, Sun HC, Zhou J. 2013. miR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. Carcinogenesis 34:2071-2079. http://dx.doi.org/10.1093/carcin/bgt160.
65. Sun X, Zhang J, Hou Z, Han Q, Zhang C, Tian Z. 2015. miR-146a is directly regulated by STAT3 in human hepatocellular carcinoma cells and involved in anti-tumor immune suppression. Cell Cycle 14:243-252. http://dx.doi.org/10.4161/15384101.2014.977112.
66. Peng Q, Li S, Lao X, Chen Z, Li R, Deng Y, Qin X. 2014. The association of common functional polymorphisms in mir-146a and mir-196a2 and hepatocellular carcinoma risk: evidence from a metaanalysis. Medicine (Baltimore, MD) 93:e252. http://dx.doi.org/10.1097/MD.0000000000000252.
67. Shirasaki T, Honda M, Shimakami T, Horii R, Yamashita T, Sakai Y, Sakai A, Okada H, Watanabe R, Murakami S, Yi M, Lemon SM, Kaneko S. 2013. MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol 87:5270-5286. http://dx.doi.org/10.1128/JVI.03022-12.
68. Singaravelu R, Chen R, Lyn RK, Jones DM, O'Hara S, Rouleau Y, Cheng J, Srinivasan P, Nasheri N, Russell RS, Tyrrell DL, Pezacki JP. 2014. Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. Hepatology 59:98-108. http://dx.doi.org/10.1002/hep.26634.
69. Li JF, Dai XP, Zhang W, Sun SH, Zeng Y, Zhao GY, Kou ZH, Guo Y, Yu H, Du LY, Jiang SB, Zhou YS. 2015. Upregulation of microRNA-146a by hepatitis B virus X protein contributes to hepatitis development by downregulating complement factor H. mBio 6:e02459-14. http://dx.doi.org/10.1128/mBio.02459-14.
70. Huang S, He R, Rong M, Dang Y, Chen G. 2014. Synergistic effect of miR-146a mimic and cetuximab on hepatocellular carcinoma cells. Biomed Res Int 2014:384121. http://dx.doi.org/10.1155/2014/384121.
71. Suzuki R, Matsuda M, Watashi K, Aizaki H, Matsuura Y, Wakita T, Suzuki T. 2013. Signal peptidase complex subunit 1 participates in the assembly of hepatitis C virus through an interaction with E2 and NS2. PLoS Pathog 9:e1003589. http://dx.doi.org/10.1371/journal.ppat.1003589.
72. Yamaguchi A, Tazuma S, Nishioka T, Ohishi W, Hyogo H, Nomura S, Chayama K. 2005. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci 50:1361-1371. http://dx.doi.org/10.1007/s10620-005-2788-1.
73. Syed GH, Amako Y, Siddiqui A. 2010. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 21:33-40. http://dx.doi.org/10.1016/j.tem.2009.07.005.
74. Ramiere C, Rodriguez J, Enache LS, Lotteau V, Andre P, Diaz O. 2014. Activity of hexokinase is increased by its interaction with hepatitis C virus protein NS5A. J Virol 88:3246-3254. http://dx.doi.org/10.1128/JVI.02862-13.